Ring Christine 4

What Happened
Christine Ring, Chief Legal Officer of Nurix Therapeutics (NRIX), sold 8,148 shares on March 2, 2026 in an open‑market transaction. The weighted average sale price was $15.44, for total proceeds of approximately $125,793. This was a sale (S) and not a purchase; such sales are often routine and, in this case, were executed under a pre‑existing Rule 10b5‑1 trading plan.

Key Details

• Transaction date: 2026-03-02 (reported same day, Form 4 filed 2026-03-02).
• Shares sold: 8,148; weighted average sale price: $15.44; total proceeds ≈ $125,793.
• Price range reported: lowest $15.16, highest $15.845; the filing notes the reporting person can provide a breakdown of quantities at each price upon request.
• Footnote: Transaction effected pursuant to a Rule 10b5‑1 trading plan.
• Shares owned after transaction: not specified in the provided filing.
• No indication in the filing that the reporting person is a 10% owner.
• Filing appears timely (no late‑filing flag noted).

Context
Sales under Rule 10b5‑1 plans are pre‑scheduled and commonly used by insiders to sell shares without signaling a change in their view of the company. This transaction represents a modest dollar amount relative to many insider trades; it is factual data rather than an indicator of company performance.